Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398820 | 0.91 | ROCK2 (0.48) | ROCK2ROCK1CCR2CXCR4ALDH1A1 | |
| SCHEMBL3314149 | 0.89 | CYP2A13 (0.40) | ALDH1A1MEN1KMT2AACHESIGMAR1 | |
| SCHEMBL3311613 | 0.88 | ROCK2 (0.46) | ROCK2ROCK1KMT2AACHESIGMAR1 | |
| SCHEMBL3314976 | 0.87 | ACHE (0.46) | ROCK2ROCK1CCR2ATMMEN1 | |
| SCHEMBL3311628 | 0.85 | ROCK1 (0.51) | ROCK2ROCK1CCR2CXCR4ALDH1A1 | |
| SCHEMBL3311507 | 0.85 | ROCK2 (0.42) | ROCK2ROCK1CCR2ALDH1A1MEN1 | |
| SCHEMBL3319720 | 0.84 | ROCK2 (0.38) | ROCK2ROCK1CCR2L3MBTL1 | |
| SCHEMBL3316802 | 0.84 | ACHE (0.49) | ROCK2ROCK1MEN1KMT2AACHE | |
| SCHEMBL3316973 | 0.83 | ROCK2 (0.48) | ROCK2ROCK1CCR2ALDH1A1ATM | |
| SCHEMBL3316860 | 0.83 | L3MBTL1 (0.42) | ALDH1A1KMT2AL3MBTL1SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2114920-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | ROCK2 6/4885ROCK1 5/4885CCR2 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.